# Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents

> **NCT02621164** · PHASE3 · COMPLETED · sponsor: **SK Chemicals Co., Ltd.** · enrollment: 454 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **BIOLOGICAL:** NBP607-QIV
- **BIOLOGICAL:** Agrippal S1

## Key facts

- **NCT ID:** NCT02621164
- **Lead sponsor:** SK Chemicals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-02
- **Final completion:** 2015-06
- **Target enrollment:** 454 (ACTUAL)
- **Last updated:** 2015-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02621164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02621164, "Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02621164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*